References

References

1. Malaysia National Cancer Registry Report 2012-2016. Malaysia: National Cancer Registry Department; 2019. 116 p. Report no.: 5.
2. American Cancer Society. Treatment of Breast Cancer by Stage [Internet]. [updated 2019 Sept 18; cited 2020 Dec 4].
Available from: https://www.cancer.org/cancer/breast-cancer/treatment/treatment-of-breast-cancer-by-stage.html
3. Breast Cancer Stages: 0 Through IV [Internet]. Breastcancer.org. 2020 [cited 2021 Jan 30].
Available from: https://www.breastcancer.org/symptoms/diagnosis/staging
4. Preserva Physical Therapy. Breast Cancer Types: What Your Type Means [image on internet]. 2019 [cited 2021 Jan 29].
Available from: https://preservagroup.com/breast-cancer-types-what-your-type-means/
5. Centers for Disease Control and Prevention. What Is Breast Cancer? [Internet]. 2020 [updated 2020 Sept 14; cited 2020 Dec 4].
Available from: https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm
6. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):236–44.
7. Devi CRB, Tang TS, Corbex M. Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia. Int J Cancer. 2012 Dec 15;131(12):2869–77.
8. Clinical Practice Guidelines 2019 Management of Breast Cancer (Third Edition). Malaysia: Malaysian Health Technology Assessment Section (MaHTAS); 2019. 124 p.
9. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al. Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014 Jul 1;32(19):2078–99.
10. Mayo Clinic. Breast MRI [Internet]. 2019 [cited 2021 Mar 3].
Available from: https://www.mayoclinic.org/tests-procedures/breast-mri/about/pac-20384809
11. Breastcancer.org. HER2 Status [Internet]. 2020 [updated 2020 Sept 21; cited 2020 Dec 4].
Available from: https://www.breastcancer.org/symptoms/diagnosis/her2
12. Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl P-O, Holm K, et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol. 2010 Apr 10;28(11):1813–20.
13. Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, et al. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. JCO. 2014 Oct 20;32(33):3744–52.
14. Lv S, Wang Y, Sun T, Wan D, Sheng L, Li W, et al. Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis. ORT. 2018;41(7–8):450–5.
15. Telli ML, Chang ET, Kurian AW, Keegan THM, McClure LA, Lichtensztajn D, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011 Jun;127(2):471–8.
16. Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, et al. Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 Sept 10;36(26):2736–40.
17. Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017 Apr;77(6):671–7.
18. Campen CJ. Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner. JADPRO [Internet]. 2017 Dec 1 [cited 2021 Mar 3];8(7).
Available from: http://www.advancedpractitioner.com/issues/volume-8,-number-7-(novdec-2017)/integrating-biosimilars-into-oncology-practice-implications-for-the-advanced-practitioner.aspx
19. U.S. Food and Drug Administration. Generic Drug Facts [Internet]. United States: U.S. Food and Drug Administration; 2018 [cited 2021 Mar 3];
Available from: https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
20. Lu C, Jacob EC. Biosimilars: Not Simply Generics [Internet]. 2019 June 18 [cited 2020 Dec 4].
Available from: https://www.uspharmacist.com/article/biosimilars-not-simply-generics
21. Fong LF. Drastic cancer drug price drop to benefit patients [Internet]. The Star; 2019 [cited 2020 Mac 3].
Available from: https://www.thestar.com.my/news/nation/2019/04/15/drastic-cancer-drug-price-drop-to-benefit-patients/
22. Guidance document and guidelines for registration of biosimilar in Malaysia. Malaysia: National Pharmaceutical Control Bureau; 2008 August. 33 p.
23. Smeeding J, Malone DC, Ramchandani M, Stolshek B, Green L, Schneider P. Biosimilars: Considerations for Payers. P T. 2019 Jan;44(2):54–63.
24. Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 2018 Mar;78(4):463–78.
25. U.S. Food and Drug Administration. Biosimilars [Internet]. United States: U.S. Food and Drug Administration; 2020 [updated 2020 Mac 2; cited 2020 Dec 4].
Available from: https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
26. Singh SC, Bagnato KM. The Economic Implications of Biosimilars. AJMC [Internet]. 2015 [cited 2020 Dec 4];21(16 Suppl):s331-40.
Available from: https://www.ajmc.com/view/ace0039_dec15_biosimilars_singhbagnato